Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Operating Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Operating Leases for 6 consecutive years, with $54.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 10.38% to $54.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.4 million through Dec 2025, down 10.38% year-over-year, with the annual reading at $54.4 million for FY2025, 10.38% down from the prior year.
  • Operating Leases for Q4 2025 was $54.4 million at TScan Therapeutics, down from $56.3 million in the prior quarter.
  • The five-year high for Operating Leases was $60.7 million in Q4 2024, with the low at $3.0 million in Q3 2022.
  • Average Operating Leases over 5 years is $39.8 million, with a median of $53.8 million recorded in 2023.
  • The sharpest move saw Operating Leases crashed 36.74% in 2022, then surged 1637.45% in 2023.
  • Over 5 years, Operating Leases stood at $4.4 million in 2021, then soared by 1107.04% to $53.0 million in 2022, then rose by 11.56% to $59.1 million in 2023, then grew by 2.7% to $60.7 million in 2024, then dropped by 10.38% to $54.4 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $54.4 million, $56.3 million, and $58.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.